Xi’an Salus Nutra Inc Established in 2015 and located in Hi-Tech industrial Zone in xi’an city, which is the most advanced area in northwest china . Salus Nutra is a professional company specialized in natural plant extracts, collagen and high technology chemical API field in scientific research, producing and marketing.

Our products are mainly used in healthcare supplement, chemicals ,pharmaceutical, cosmetics and food additives. We are also engaged in supplying customization OEM service to help customers choose their right ingredients and develop their broad markets .

Our factory is located in BaoJi ,shaanxi province, it coveries an area of XX acres and equips with 2 standard production workshops meet with State Health Standards ,meanwhile employs more than 500 people with well-educated, including undergraduate, Postgraduate and some technical persons with rich experience.

Salus is committed to supplying safe, pure and healthy products that meet the high expectations of our customers. Experienced and dedicated members of the Quality and food safety Department work to provide in-depth analyses, testing and monitoring of our products, during and after the manufacturing processes and ensure the quality and safety according to the highest standards.

We are based on the honest and mutual benefits, rely on the reliable quality and best after-sale service to make good reputations both online and offline. Now it shares a great popularities from the customers at overseas. Our primary goal aims to solve customer problems through research & development & technical service .

If you have any doubts or confusion, YES, Salus will present the exactly right answer.

Supply Dabigatran Etexilate Mesylate

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
|Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.
|Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults